NASDAQ:PRAH - PRA Health Sciences Stock Price, Forecast & News

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) announced its earnings results on Wednesday, October, 30th. The medical research company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.29 by $0.03. The medical research company had revenue of $780.70 million for the quarter, compared to the consensus estimate of $771.64 million. PRA Health Sciences had a return on equity of 27.73% and a net margin of 8.00%. The company's revenue was up 8.8% on a year-over-year basis. During the same period last year, the business posted $1.13 EPS. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of $5.07-$5.12 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.07. The company issued revenue guidance of $3.02-$3.10 billion, compared to the consensus revenue estimate of $3.06 billion.

10 equities research analysts have issued 12-month price targets for PRA Health Sciences' shares. Their forecasts range from $100.00 to $123.00. On average, they anticipate PRA Health Sciences' stock price to reach $116.44 in the next twelve months. This suggests a possible upside of 12.8% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PRA Health Sciences.

Press coverage about PRAH stock has trended somewhat negative recently, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PRA Health Sciences earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for PRA Health Sciences.

PRA Health Sciences saw a increase in short interest in January. As of January 15th, there was short interest totalling 2,090,000 shares, an increase of 29.8% from the December 31st total of 1,610,000 shares. Based on an average trading volume of 501,500 shares, the short-interest ratio is presently 4.2 days. Approximately 3.3% of the shares of the stock are short sold. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Geovax Labs (GOVX), Intrexon (XON), Sorrento Therapeutics (SRNE), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Paypal (PYPL), Applied Materials (AMAT), Veeva Systems (VEEV), Lam Research (LRCX), Netflix (NFLX), Arista Networks (ANET) and Walt Disney (DIS).

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.29%), Virginia Retirement Systems ET AL (0.28%), California Public Employees Retirement System (0.23%), Reilly Financial Advisors LLC (0.18%), Assenagon Asset Management S.A. (0.16%) and Artemis Investment Management LLP (0.15%). Company insiders that own PRA Health Sciences stock include Fund Holdings LP Kkr and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Strs Ohio, Gateway Investment Advisers LLC, California Public Employees Retirement System, Sciencast Management LP, Arizona State Retirement System, Scout Investments Inc. and Nisa Investment Advisors LLC. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Three Peaks Capital Management LLC, Reilly Financial Advisors LLC, Clark Capital Management Group Inc., Campbell & CO Investment Adviser LLC, Fulton Breakefield Broenniman LLC, New York State Teachers Retirement System and FNY Investment Advisers LLC. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $103.27.

PRA Health Sciences has a market capitalization of $6.53 billion and generates $2.87 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $3.93 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.View Additional Information About PRA Health Sciences.

The official website for PRA Health Sciences is http://www.prahs.com/.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]